MicroRNA-455-3p improves synaptic, cognitive functions and extends lifespan: Relevance to Alzheimer's disease

Subodh Kumar1, Hallie Morton1, Neha Sawant1

  • 1Internal Medicine Department, Texas Tech University Health Sciences Center, Lubbock, TX, USA.

Redox Biology
|November 15, 2021
PubMed
Abstract

Insights

MicroRNA-455-3p enhances lifespan and cognitive function in mice by improving mitochondrial and synaptic activities. Its depletion has detrimental effects, highlighting its role in aging and Alzheimer's disease.

Area of Science:

  • Neuroscience
  • Genetics
  • Molecular Biology

Background:

  • MicroRNA-455-3p is a conserved miRNA implicated in cellular functions.
  • Previous in vitro studies suggested a protective role against Alzheimer's disease (AD) toxicities, including reducing amyloid-beta (Aβ) and improving mitochondrial and synaptic health.
  • The in vivo function of miR-455-3p in learning and memory, particularly in the context of AD, remained to be elucidated.

Purpose of the Study:

  • To investigate the in vivo function of microRNA-455-3p (miR-455-3p) in learning and memory.
  • To determine the impact of miR-455-3p on lifespan, cognitive function, mitochondrial biogenesis, mitochondrial dynamics, and synaptic activity.
  • To establish the relevance of miR-455-3p to aging and Alzheimer's disease (AD) through the development of novel mouse models.

Main Methods:

  • Generation of transgenic (TG) and knockout (KO) mouse models for miR-455-3p.
  • Assessment of lifespan, cognitive function using the Morris water maze test, mitochondrial biogenesis, mitochondrial dynamics, mitochondrial morphology, dendritic spine density, synapse numbers, and synaptic activity in TG and KO mice compared to wild-type (WT) controls.

Main Results:

  • miR-455-3p TG mice exhibited a 5-month lifespan extension compared to WT, while KO mice showed a 4-month reduction.
  • TG mice demonstrated improved cognitive behavior, spatial learning, and memory, whereas KO mice showed deficits.
  • Enhanced mitochondrial biogenesis, dynamics, and synaptic activities were observed in TG mice, with reductions in KO mice, indicating protective effects of overexpression and deleterious effects of depletion.

Conclusions:

  • Overexpressed miR-455-3p confers protective effects on lifespan, cognitive function, and mitochondrial and synaptic health in mice.
  • Depleted miR-455-3p has deleterious effects on these parameters, underscoring its critical role.
  • The generated miR-455-3p TG and KO mouse models serve as valuable tools for studying aging and age-related diseases like AD.

Related Concept Videos

Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
293
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
235
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
740